Back to top
Navidea Biopharmaceuticals (NAVB)
(Delayed Data from OTC)
$0.00 USD
0.00
12,071
0.00 (150.00%)
Updated Nov 6, 2024 02:35 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked StocksBalance Sheet
Fiscal Year End for Navidea Biopharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | -99,999 | 2 | 4 | 3 | 1 |
| Receivables | NA | 0 | 0 | 3 | 1 |
| Notes Receivable | NA | 0 | 0 | 0 | 0 |
| Inventories | NA | 0 | 0 | 0 | 0 |
| Other Current Assets | NA | 1 | 1 | 1 | 1 |
| Total Current Assets | NA | 3 | 5 | 7 | 3 |
| Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
| Investments & Advances | NA | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
| Deferred Charges | NA | 0 | 0 | 0 | 0 |
| Intangibles | NA | 1 | 1 | 1 | 0 |
| Deposits & Other Assets | NA | 0 | 0 | 0 | 1 |
| Total Assets | NA | 4 | 7 | 8 | 4 |
| Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
|---|---|---|---|---|---|
| Notes Payable | NA | 1 | 0 | 1 | 0 |
| Accounts Payable | NA | 2 | 1 | 1 | 1 |
| Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
| Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
| Accrued Expenses | NA | 6 | 3 | 3 | 2 |
| Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
| Other Current Liabilities | NA | 1 | 0 | 0 | 0 |
| Total Current Liabilities | NA | 10 | 5 | 5 | 4 |
| Mortgages | NA | 0 | 0 | 0 | 0 |
| Deferred Taxes/Income | NA | 1 | 1 | 1 | 1 |
| Convertible Debt | NA | 0 | 0 | 0 | 0 |
| Long-Term Debt | NA | 2 | 0 | 0 | 0 |
| Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
| Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
| Total Liabilities | NA | 13 | 6 | 6 | 5 |
| Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
|---|---|---|---|---|---|
| Preferred Stock | NA | 0 | 0 | -10 | 0 |
| Common Stock (Par) | NA | 0 | 0 | -5 | 0 |
| Capital Surplus | NA | 379 | 370 | 375 | 346 |
| Retained Earnings | NA | -388 | -371 | -359 | -348 |
| Other Equity | NA | 0 | 1 | 1 | 1 |
| Treasury Stock | NA | 0 | 0 | 0 | 0 |
| Total Shareholder's Equity | NA | -8 | 1 | 2 | -1 |
| Total Liabilities & Shareholder's Equity | NA | 4 | 7 | 8 | 4 |
| Total Common Equity | 0 | -8 | 1 | 12 | -1 |
| Shares Outstanding | 100.00 | 32.10 | 30.10 | 26.60 | 18.00 |
| Book Value Per Share | 0.00 | -0.25 | 0.02 | 0.46 | -0.05 |
Fiscal Year End for Navidea Biopharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
| 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | 4 |
| Receivables | NA | NA | NA | NA | 0 |
| Notes Receivable | NA | NA | NA | NA | 0 |
| Inventories | NA | NA | NA | NA | 0 |
| Other Current Assets | NA | NA | NA | NA | 0 |
| Total Current Assets | NA | NA | NA | NA | 5 |
| Net Property & Equipment | NA | NA | NA | NA | 0 |
| Investments & Advances | NA | NA | NA | NA | 0 |
| Other Non-Current Assets | NA | NA | NA | NA | 0 |
| Deferred Charges | NA | NA | NA | NA | 0 |
| Intangibles | NA | NA | NA | NA | 1 |
| Deposits & Other Assets | NA | NA | NA | NA | 0 |
| Total Assets | NA | NA | NA | NA | 6 |
| Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
|---|---|---|---|---|---|
| Notes Payable | NA | NA | NA | NA | 1 |
| Accounts Payable | NA | NA | NA | NA | 2 |
| Current Portion Long-Term Debt | NA | NA | NA | NA | 0 |
| Current Portion Capital Leases | NA | NA | NA | NA | 0 |
| Accrued Expenses | NA | NA | NA | NA | 4 |
| Income Taxes Payable | NA | NA | NA | NA | 0 |
| Other Current Liabilities | NA | NA | NA | NA | 1 |
| Total Current Liabilities | NA | NA | NA | NA | 8 |
| Mortgages | NA | NA | NA | NA | 0 |
| Deferred Taxes/Income | NA | NA | NA | NA | 1 |
| Convertible Debt | NA | NA | NA | NA | 0 |
| Long-Term Debt | NA | NA | NA | NA | 0 |
| Non-Current Capital Leases | NA | NA | NA | NA | 0 |
| Other Non-Current Liabilities | NA | NA | NA | 0 | |
| Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
| Total Liabilities | NA | NA | NA | NA | 9 |
| Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
|---|---|---|---|---|---|
| Preferred Stock | NA | NA | NA | NA | 0 |
| Common Stock (Par) | NA | NA | NA | NA | 0 |
| Capital Surplus | NA | NA | NA | NA | 382 |
| Retained Earnings | NA | NA | NA | NA | -386 |
| Other Equity | NA | NA | NA | NA | 0 |
| Treasury Stock | NA | NA | NA | NA | 0 |
| Total Shareholder's Equity | NA | NA | NA | NA | -3 |
| Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 6 |
| Total Common Equity | 0 | 0 | 0 | 0 | -3 |
| Shares Outstanding | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |